NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis → Digitizing the $11T commodities sector with one tiny stock (From Resource Stock Digest) (Ad) Free GMAB Stock Alerts $28.01 +0.01 (+0.04%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$27.90▼$28.5350-Day Range$27.46▼$30.8352-Week Range$26.32▼$42.72Volume545,901 shsAverage Volume573,898 shsMarket Capitalization$18.52 billionP/E Ratio23.34Dividend YieldN/APrice Target$48.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside73.2% Upside$48.50 Price TargetShort InterestBearish0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth27.03%From $1.11 to $1.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector336th out of 931 stocksPharmaceutical Preparations Industry157th out of 433 stocks 3.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageGenmab A/S has only been the subject of 3 research reports in the past 90 days.Read more about Genmab A/S's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.45% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Genmab A/S has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 2.6 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search Interest9 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 27.03% in the coming year, from $1.11 to $1.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 23.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.64.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 23.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 142.32.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesMay 27 at 10:16 AM | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 23, 2024 | finanznachrichten.deGenmab A/S: Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | globenewswire.comGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | businesswire.comGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 21, 2024 | businesswire.comGenmab Completes Acquisition of ProfoundBioMay 21, 2024 | globenewswire.comGenmab Completes Acquisition of ProfoundBioMay 21, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 21, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives Buy Rating from HC WainwrightMay 20, 2024 | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 15, 2024 | finance.yahoo.comMarket Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'May 14, 2024 | businesswire.comGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressMay 13, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 7, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 3, 2024 | markets.businessinsider.comOptimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy RatingMay 3, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call TranscriptMay 2, 2024 | seekingalpha.comGenmab A/S 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | globenewswire.comGenmab Announces Financial Results for the First Quarter of 2024May 1, 2024 | seekingalpha.comGenmab: A Complicated TaleApril 30, 2024 | msn.comPfizer, Genmab cervical cancer therapy wins full FDA approvalApril 29, 2024 | globenewswire.comTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerApril 29, 2024 | businesswire.comTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerApril 29, 2024 | businesswire.comFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerApril 29, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 22, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 20, 2024 | finance.yahoo.comGenmab A/S (GMAB)See More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/28/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$48.50 High Stock Price Target$50.00 Low Stock Price Target$46.00 Potential Upside/Downside+70.4%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$1.20 Trailing P/E Ratio23.73 Forward P/E Ratio25.65 P/E Growth1.02Net Income$631.91 million Net Margins30.74% Pretax Margin39.74% Return on Equity18.90% Return on Assets16.83% Debt Debt-to-Equity RatioN/A Current Ratio12.46 Quick Ratio12.42 Sales & Book Value Annual Sales$2.39 billion Price / Sales7.87 Cash Flow$1.26 per share Price / Cash Flow22.58 Book Value$6.95 per share Price / Book4.10Miscellaneous Outstanding Shares661,230,000Free Float651,047,000Market Cap$18.83 billion OptionableOptionable Beta1.00 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.14MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $637.57kMr. Christopher Cozic (Age 45)Executive VP & Chief People Officer Comp: $782.47kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $695.53kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.92kDr. Judith V. Klimovsky M.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.17MDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.39kMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKAlnylam PharmaceuticalsNASDAQ:ALNYTeva Pharmaceutical IndustriesNYSE:TEVARoyalty PharmaNASDAQ:RPRXBeiGeneNASDAQ:BGNEView All CompetitorsInstitutional OwnershipAtria Investments IncSold 13,398 shares on 5/21/2024Ownership: 0.005%Dynasty Wealth Management LLCBought 13,472 shares on 5/16/2024Ownership: 0.002%Bayesian Capital Management LPBought 11,436 shares on 5/16/2024Ownership: 0.002%Bamco Inc. NYSold 66,714 shares on 5/15/2024Ownership: 0.011%Mount Yale Investment Advisors LLCBought 9,113 shares on 5/15/2024Ownership: 0.001%View All Institutional Transactions GMAB Stock Analysis - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price target for 2024? 13 brokers have issued 12 month price targets for Genmab A/S's stock. Their GMAB share price targets range from $46.00 to $50.00. On average, they predict the company's stock price to reach $48.50 in the next year. This suggests a possible upside of 73.2% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2024? Genmab A/S's stock was trading at $31.84 at the beginning of the year. Since then, GMAB shares have decreased by 12.0% and is now trading at $28.01. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 7.6% from the April 30th total of 2,750,000 shares. Based on an average daily volume of 520,800 shares, the short-interest ratio is presently 5.7 days. Currently, 0.5% of the company's stock are sold short. View Genmab A/S's Short Interest. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) posted its quarterly earnings results on Thursday, May, 2nd. The company reported $0.16 EPS for the quarter, hitting analysts' consensus estimates of $0.16. The company had revenue of $603.30 million for the quarter, compared to analyst estimates of $594.23 million. Genmab A/S had a trailing twelve-month return on equity of 18.90% and a net margin of 30.74%. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), iShares Biotechnology ETF (IBB), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and WisdomTree BioRevolution Fund (WDNA).Goldman Sachs Future Health Care Equity ETF (GDOC). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital International Investors (0.66%), Oppenheimer Asset Management Inc. (0.03%), Raymond James & Associates (0.03%), US Bancorp DE (0.02%), Williams Jones Wealth Management LLC. (0.01%) and Bamco Inc. NY (0.01%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMAB) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
